Head to Head Analysis: Sight Sciences (SGHT) & Its Rivals

Sight Sciences (NASDAQ:SGHT) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Sight Sciences to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Sight Sciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Sight Sciences’ rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Sight Sciences and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1	2	5	0	2.50
Sight Sciences Competitors	4281	10558	18338	829	2.46

Sight Sciences presently has a consensus target price of $9.62, indicating a potential downside of 12.58%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.19%. Given Sight Sciences’ rivals higher probable upside, analysts clearly believe Sight Sciences has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Sight Sciences and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sight Sciences	$77.36 million	-$38.43 million	-21.17
Sight Sciences Competitors	$1.87 billion	$138.21 million	12.55

Sight Sciences’ rivals have higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Sight Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-32.13%	-42.41%	-21.95%
Sight Sciences Competitors	-276.78%	-149.08%	-21.73%

Summary

Sight Sciences rivals beat Sight Sciences on 7 of the 13 factors compared.

Sight Sciences Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.